FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4291952015> ?p ?o ?g. }

• W4291952015 endingPage "326" @default.
• W4291952015 startingPage "317" @default.
• W4291952015 abstract "PurposeThe paper aims to evaluate the efficacy and safety of 223Ra in patients who progressed after first-line androgen deprivation therapy.Patients and methodsEXCAAPE (NCT03002220) was a multicentre, single-arm, open-label, non-controlled phase IIa trial in 52 patients with metastatic castration-resistant prostate cancer and asymptomatic bone metastases who have progressed on abiraterone acetate or enzalutamide, up to six doses of 223Ra (55 kBq/kg of body weight per month). The primary end-point was radiographic progression-free survival (rPFS). Secondary end-points included rPFS based on androgen receptor splice variant 7 (AR-V7) expression in circulating tumour cells (CTCs), overall survival, and safety.ResultsMedian rPFS was 5.5 months (95% CI 5.3–5.5). Median rPFS of patients with AR-V7(−) CTCs was longer than that of patients with AR-V7(+) CTCs (5.5 versus 2.2 months, respectively; P = 0.056). Median overall survival was 14.8 months (95% CI 11.2–not reached) and was significantly greater for AR-V7(−) patients than for AR-V7(+) patients (14.8 months versus 3.5 months, respectively; P < 0.01). 223Ra was well tolerated; anaemia and thrombocytopenia were the most common grade 3/4 adverse events (5.8% and 11.5%, respectively).Conclusions223Ra seems to be a reasonable treatment for patients with metastatic castration-resistant prostate cancer and asymptomatic bone metastases progressing on novel hormonal therapy and had an acceptable safety profile." @default.
• W4291952015 created "2022-08-16" @default.
• W4291952015 creator A5001994148 @default.
• W4291952015 creator A5004800809 @default.
• W4291952015 creator A5010040304 @default.
• W4291952015 creator A5023045485 @default.
• W4291952015 creator A5026678528 @default.
• W4291952015 creator A5035744703 @default.
• W4291952015 creator A5041245337 @default.
• W4291952015 creator A5048494721 @default.
• W4291952015 creator A5056893451 @default.
• W4291952015 creator A5058430018 @default.
• W4291952015 creator A5060049578 @default.
• W4291952015 creator A5068543301 @default.
• W4291952015 creator A5069681103 @default.
• W4291952015 creator A5073753280 @default.
• W4291952015 creator A5074076730 @default.
• W4291952015 creator A5079620361 @default.
• W4291952015 creator A5082318397 @default.
• W4291952015 creator A5084085052 @default.
• W4291952015 creator A5088085188 @default.
• W4291952015 date "2022-09-01" @default.
• W4291952015 modified "2023-10-18" @default.
• W4291952015 title "Radium-223 for patients with metastatic castration-resistant prostate cancer with asymptomatic bone metastases progressing on first-line abiraterone acetate or enzalutamide: A single-arm phase II trial" @default.
• W4291952015 cites W1494447899 @default.
• W4291952015 cites W1844925317 @default.
• W4291952015 cites W1975577875 @default.
• W4291952015 cites W2103793201 @default.
• W4291952015 cites W2116607127 @default.
• W4291952015 cites W2129128353 @default.
• W4291952015 cites W2141454098 @default.
• W4291952015 cites W2156923287 @default.
• W4291952015 cites W2170668585 @default.
• W4291952015 cites W2170731023 @default.
• W4291952015 cites W2419426348 @default.
• W4291952015 cites W2483834070 @default.
• W4291952015 cites W2486721152 @default.
• W4291952015 cites W2659875471 @default.
• W4291952015 cites W2811305164 @default.
• W4291952015 cites W2883299186 @default.
• W4291952015 cites W2897146989 @default.
• W4291952015 cites W2907732987 @default.
• W4291952015 cites W2908775546 @default.
• W4291952015 cites W2911490798 @default.
• W4291952015 cites W2972620913 @default.
• W4291952015 cites W2975059798 @default.
• W4291952015 cites W2976335348 @default.
• W4291952015 cites W2977469640 @default.
• W4291952015 cites W2978842445 @default.
• W4291952015 cites W2994239644 @default.
• W4291952015 cites W2999047517 @default.
• W4291952015 cites W3033684926 @default.
• W4291952015 cites W3088473878 @default.
• W4291952015 cites W3093699595 @default.
• W4291952015 cites W3119005666 @default.
• W4291952015 cites W3191534679 @default.
• W4291952015 cites W2468073370 @default.
• W4291952015 doi "https://doi.org/10.1016/j.ejca.2022.06.057" @default.
• W4291952015 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35981452" @default.
• W4291952015 hasPublicationYear "2022" @default.
• W4291952015 type Work @default.
• W4291952015 citedByCount "1" @default.
• W4291952015 countsByYear W42919520152023 @default.
• W4291952015 crossrefType "journal-article" @default.
• W4291952015 hasAuthorship W4291952015A5001994148 @default.
• W4291952015 hasAuthorship W4291952015A5004800809 @default.
• W4291952015 hasAuthorship W4291952015A5010040304 @default.
• W4291952015 hasAuthorship W4291952015A5023045485 @default.
• W4291952015 hasAuthorship W4291952015A5026678528 @default.
• W4291952015 hasAuthorship W4291952015A5035744703 @default.
• W4291952015 hasAuthorship W4291952015A5041245337 @default.
• W4291952015 hasAuthorship W4291952015A5048494721 @default.
• W4291952015 hasAuthorship W4291952015A5056893451 @default.
• W4291952015 hasAuthorship W4291952015A5058430018 @default.
• W4291952015 hasAuthorship W4291952015A5060049578 @default.
• W4291952015 hasAuthorship W4291952015A5068543301 @default.
• W4291952015 hasAuthorship W4291952015A5069681103 @default.
• W4291952015 hasAuthorship W4291952015A5073753280 @default.
• W4291952015 hasAuthorship W4291952015A5074076730 @default.
• W4291952015 hasAuthorship W4291952015A5079620361 @default.
• W4291952015 hasAuthorship W4291952015A5082318397 @default.
• W4291952015 hasAuthorship W4291952015A5084085052 @default.
• W4291952015 hasAuthorship W4291952015A5088085188 @default.
• W4291952015 hasConcept C121608353 @default.
• W4291952015 hasConcept C126322002 @default.
• W4291952015 hasConcept C126894567 @default.
• W4291952015 hasConcept C143998085 @default.
• W4291952015 hasConcept C203092338 @default.
• W4291952015 hasConcept C2775832370 @default.
• W4291952015 hasConcept C2776286101 @default.
• W4291952015 hasConcept C2776541429 @default.
• W4291952015 hasConcept C2776551883 @default.
• W4291952015 hasConcept C2776694085 @default.
• W4291952015 hasConcept C2777899217 @default.
• W4291952015 hasConcept C2777910003 @default.
• W4291952015 hasConcept C2780192828 @default.
• W4291952015 hasConcept C2780739268 @default.
• W4291952015 hasConcept C2781190966 @default.

• next